BioCentury
ARTICLE | Company News

Axerion, MedImmune in deal for AD mAb

May 2, 2012 12:52 AM UTC

Axerion Therapeutics Inc. (New Haven, Conn.) granted MedImmune LLC exclusive rights to develop and commercialize a preclinical mAb for Alzheimer's disease that inhibits the interaction between prion protein ( PRNP; PrP; CD230) receptor and oligomeric beta amyloid. Axerion will receive an upfront payment and R&D funding; it also is eligible for milestones and royalties. Details were not disclosed. MedImmune is the biologics unit of AstraZeneca plc (LSE:AZN; NYSE:AZN). ...